Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.

Kim J, Lana B, Torelli S, Ryan D, Catapano F, Ala P, Luft C, Stevens E, Konstantinidis E, Louzada S, Fu B, Paredes-Redondo A, Chan AE, Yang F, Stemple DL, Liu P, Ketteler R, Selwood DL, Muntoni F, Lin YY.

EMBO Rep. 2019 Sep 30:e47967. doi: 10.15252/embr.201947967. [Epub ahead of print]

2.

Commentary: Reproducible science, why protocols matter.

Selwood DL.

Chem Biol Drug Des. 2019 Jun;93(6):975-978. doi: 10.1111/cbdd.13538. No abstract available.

PMID:
31343120
3.

The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca2+-Activated K+ Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing.

Tabatabaee S, Baker D, Selwood DL, Whalley BJ, Stephens GJ.

Pharmaceuticals (Basel). 2019 Jul 4;12(3). pii: E104. doi: 10.3390/ph12030104.

4.

N10 -carbonyl-substituted phenothiazines inhibiting lipid peroxidation and associated nitric oxide consumption powerfully protect brain tissue against oxidative stress.

Keynes RG, Karchevskaya A, Riddall D, Griffiths CH, Bellamy TC, Chan AWE, Selwood DL, Garthwaite J.

Chem Biol Drug Des. 2019 Sep;94(3):1680-1693. doi: 10.1111/cbdd.13572. Epub 2019 Jun 12.

5.

Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

Gregson A, Thompson K, Tsirka SE, Selwood DL.

F1000Res. 2019 Mar 1;8. pii: F1000 Faculty Rev-245. doi: 10.12688/f1000research.16495.1. eCollection 2019. Review.

6.

Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets.

Briston T, Selwood DL, Szabadkai G, Duchen MR.

Trends Pharmacol Sci. 2019 Jan;40(1):50-70. doi: 10.1016/j.tips.2018.11.004. Epub 2018 Dec 6. Review.

PMID:
30527591
7.

Identification of Kinases and Phosphatases That Regulate ATG4B Activity by siRNA and Small Molecule Screening in Cells.

Pengo N, Prak K, Costa JR, Luft C, Agrotis A, Freeman J, Gewinner CA, Chan AWE, Selwood DL, Kriston-Vizi J, Ketteler R.

Front Cell Dev Biol. 2018 Nov 1;6:148. doi: 10.3389/fcell.2018.00148. eCollection 2018.

8.

Biophysical screening methods for extracellular domain peptide receptors, application to natriuretic peptide receptor C ligands.

Conole D, Myers SH, Mota F, Hobbs AJ, Selwood DL.

Chem Biol Drug Des. 2019 Jun;93(6):1011-1020. doi: 10.1111/cbdd.13395. Epub 2018 Oct 10.

PMID:
30218492
9.

Structure and function of L-threonine-3-dehydrogenase from the parasitic protozoan Trypanosoma brucei revealed by X-ray crystallography and geometric simulations.

Adjogatse E, Erskine P, Wells SA, Kelly JM, Wilden JD, Chan AWE, Selwood D, Coker A, Wood S, Cooper JB.

Acta Crystallogr D Struct Biol. 2018 Sep 1;74(Pt 9):861-876. doi: 10.1107/S2059798318009208. Epub 2018 Sep 3.

PMID:
30198897
10.

Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells.

Powell J, Mota F, Steadman D, Soudy C, Miyauchi JT, Crosby S, Jarvis A, Reisinger T, Winfield N, Evans G, Finniear A, Yelland T, Chou YT, Chan AWE, O'Leary A, Cheng L, Liu D, Fotinou C, Milagre C, Martin JF, Jia H, Frankel P, Djordjevic S, Tsirka SE, Zachary IC, Selwood DL.

J Med Chem. 2018 May 10;61(9):4135-4154. doi: 10.1021/acs.jmedchem.8b00210. Epub 2018 Apr 24.

11.

Architecture and hydration of the arginine-binding site of neuropilin-1.

Mota F, Fotinou C, Rana RR, Chan AWE, Yelland T, Arooz MT, O'Leary AP, Hutton J, Frankel P, Zachary I, Selwood D, Djordjevic S.

FEBS J. 2018 Apr;285(7):1290-1304. doi: 10.1111/febs.14405. Epub 2018 Feb 25.

12.

IKKγ-Mimetic Peptides Block the Resistance to Apoptosis Associated with Kaposi's Sarcoma-Associated Herpesvirus Infection.

Briggs LC, Chan AWE, Davis CA, Whitelock N, Hotiana HA, Baratchian M, Bagnéris C, Selwood DL, Collins MK, Barrett TE.

J Virol. 2017 Nov 14;91(23). pii: e01170-17. doi: 10.1128/JVI.01170-17. Print 2017 Dec 1.

13.

Big conductance calcium-activated potassium channel openers control spasticity without sedation.

Baker D, Pryce G, Visintin C, Sisay S, Bondarenko AI, Vanessa Ho WS, Jackson SJ, Williams TE, Al-Izki S, Sevastou I, Okuyama M, Graier WF, Stevenson LA, Tanner C, Ross R, Pertwee RG, Henstridge CM, Irving AJ, Schulman J, Powell K, Baker MD, Giovannoni G, Selwood DL.

Br J Pharmacol. 2017 Aug;174(16):2662-2681. doi: 10.1111/bph.13889. Epub 2017 Jul 7.

14.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
15.

Macrocycles, the edge of drug-likeness chemical space or Goldilocks zone?

Selwood DL.

Chem Biol Drug Des. 2017 Feb;89(2):164-168. doi: 10.1111/cbdd.12922. No abstract available.

PMID:
28205398
16.

Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.

Langron E, Simone MI, Delalande CM, Reymond JL, Selwood DL, Vergani P.

Br J Pharmacol. 2017 Apr;174(7):525-539. doi: 10.1111/bph.13715. Epub 2017 Feb 14.

17.

Infection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence Microscopy.

Culley S, Towers GJ, Selwood DL, Henriques R, Grove J.

Viruses. 2016 Jul 21;8(7). pii: E201. doi: 10.3390/v8070201.

18.

Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.

Jimenez-Moyano E, Ruiz A, Kløverpris HN, Rodriguez-Plata MT, Peña R, Blondeau C, Selwood DL, Izquierdo-Useros N, Moris A, Clotet B, Goulder P, Towers GJ, Prado JG.

J Virol. 2016 Sep 12;90(19):8552-62. doi: 10.1128/JVI.00819-16. Print 2016 Oct 1.

19.

Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing.

Sevastou I, Pryce G, Baker D, Selwood DL.

PLoS One. 2016 Jun 29;11(6):e0157754. doi: 10.1371/journal.pone.0157754. eCollection 2016.

20.

HIV-1 capsid is involved in post-nuclear entry steps.

Chen NY, Zhou L, Gane PJ, Opp S, Ball NJ, Nicastro G, Zufferey M, Buffone C, Luban J, Selwood D, Diaz-Griffero F, Taylor I, Fassati A.

Retrovirology. 2016 Apr 23;13:28. doi: 10.1186/s12977-016-0262-0.

21.

Ablation of Neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression.

Miyauchi JT, Chen D, Choi M, Nissen JC, Shroyer KR, Djordevic S, Zachary IC, Selwood D, Tsirka SE.

Oncotarget. 2016 Mar 1;7(9):9801-14. doi: 10.18632/oncotarget.6877.

22.

Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis.

Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker AR, Duchen MR, Szabadkai G, Baker D, Selwood DL.

J Biol Chem. 2016 Feb 26;291(9):4356-73. doi: 10.1074/jbc.M115.700385. Epub 2015 Dec 17.

23.

Phosphoinositide Modulation of Heteromeric Kv1 Channels Adjusts Output of Spiral Ganglion Neurons from Hearing Mice.

Smith KE, Browne L, Selwood DL, McAlpine D, Jagger DJ.

J Neurosci. 2015 Aug 12;35(32):11221-32. doi: 10.1523/JNEUROSCI.0496-15.2015.

24.

A new small molecule inhibitor of soluble guanylate cyclase.

Mota F, Gane P, Hampden-Smith K, Allerston CK, Garthwaite J, Selwood DL.

Bioorg Med Chem. 2015 Sep 1;23(17):5303-10. doi: 10.1016/j.bmc.2015.07.074. Epub 2015 Aug 4.

25.

Correction to Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis.

Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AW, Riddall D, Garthwaite J, Baker D, Selwood DL.

J Med Chem. 2015 Apr 23;58(8):3637. doi: 10.1021/acs.jmedchem.5b00508. Epub 2015 Apr 7. No abstract available.

26.

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D.

J Neuroimmune Pharmacol. 2015 Jun;10(2):281-92. doi: 10.1007/s11481-014-9575-8. Epub 2014 Dec 24. Review.

PMID:
25537576
27.

Small steps to new drugs for bugs.

Melander RJ, Selwood DL.

Chem Biol Drug Des. 2015 Jan;85(1):1-3. doi: 10.1111/cbdd.12482.

PMID:
25521640
28.

2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion.

Sayer JR, Walldén K, Pesnot T, Campbell F, Gane PJ, Simone M, Koss H, Buelens F, Boyle TP, Selwood DL, Waksman G, Tabor AB.

Bioorg Med Chem. 2014 Nov 15;22(22):6459-70. doi: 10.1016/j.bmc.2014.09.036. Epub 2014 Sep 28.

29.

Endothelial C-type natriuretic peptide maintains vascular homeostasis.

Moyes AJ, Khambata RS, Villar I, Bubb KJ, Baliga RS, Lumsden NG, Xiao F, Gane PJ, Rebstock AS, Worthington RJ, Simone MI, Mota F, Rivilla F, Vallejo S, Peiró C, Sánchez Ferrer CF, Djordjevic S, Caulfield MJ, MacAllister RJ, Selwood DL, Ahluwalia A, Hobbs AJ.

J Clin Invest. 2014 Sep;124(9):4039-51. doi: 10.1172/JCI74281. Epub 2014 Aug 8.

30.

N-terminal modification of VEGF-A C terminus-derived peptides delineates structural features involved in neuropilin-1 binding and functional activity.

Jia H, Aqil R, Cheng L, Chapman C, Shaikh S, Jarvis A, Chan AW, Hartzoulakis B, Evans IM, Frolov A, Martin J, Frankel P, Djordevic S, Zachary IC, Selwood DL.

Chembiochem. 2014 May 26;15(8):1161-70. doi: 10.1002/cbic.201300658. Epub 2014 Apr 25.

PMID:
24771685
31.

Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.

Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AW, Riddall D, Garthwaite J, Baker D, Selwood DL.

J Med Chem. 2014 Apr 10;57(7):2942-52. doi: 10.1021/jm401881q. Epub 2014 Mar 21. Erratum in: J Med Chem. 2015 Apr 23;58(8):3637.

32.

Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activators.

Mota F, Allerston CK, Hampden-Smith K, Garthwaite J, Selwood DL.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1075-9. doi: 10.1016/j.bmcl.2014.01.015. Epub 2014 Jan 13.

33.

A bifurcated proteoglycan binding small molecule carrier for siRNA delivery.

Gooding M, Adigbli D, Edith Chan AW, Melander RJ, MacRobert AJ, Selwood DL.

Chem Biol Drug Des. 2014 Jul;84(1):24-35. doi: 10.1111/cbdd.12295. Epub 2014 May 13.

34.

Two- and three-dimensional rings in drugs.

Aldeghi M, Malhotra S, Selwood DL, Chan AW.

Chem Biol Drug Des. 2014 Apr;83(4):450-61. doi: 10.1111/cbdd.12260.

35.

Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization.

Lo AW, Van de Water K, Gane PJ, Chan AW, Steadman D, Stevens K, Selwood DL, Waksman G, Remaut H.

J Antimicrob Chemother. 2014 Apr;69(4):1017-26. doi: 10.1093/jac/dkt467. Epub 2013 Dec 8.

36.

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.

Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C, Edith Chan AW, Amor S, Perkins V, Gerritsen WH, Ummenthum K, Peferoen-Baert R, van der Valk P, Montoya A, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D.

Brain. 2014 Jan;137(Pt 1):92-108. doi: 10.1093/brain/awt324. Epub 2013 Nov 27.

PMID:
24287115
37.

HIV-1 evades innate immune recognition through specific cofactor recruitment.

Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ.

Nature. 2013 Nov 21;503(7476):402-405. doi: 10.1038/nature12769. Epub 2013 Nov 6.

38.

Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.

Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G, Baker D.

PLoS One. 2013 Oct 9;8(10):e76907. doi: 10.1371/journal.pone.0076907. eCollection 2013.

39.

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.

Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A, Hardcastle AJ, Kooij G, de Vries HE, Amor S, Thomas SA, Ledent C, Marsicano G, Lutz B, Thompson AJ, Selwood DL, Giovannoni G, Baker D.

FASEB J. 2014 Jan;28(1):117-30. doi: 10.1096/fj.13-239442. Epub 2013 Oct 11.

PMID:
24121462
40.

Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway.

Nissen JC, Selwood DL, Tsirka SE.

J Neurochem. 2013 Nov;127(3):394-402. doi: 10.1111/jnc.12404. Epub 2013 Sep 18.

41.

Beyond the hundred dollar genome--drug discovery futures.

Selwood DL.

Chem Biol Drug Des. 2013 Jan;81(1):1-4. doi: 10.1111/cbdd.12088.

PMID:
23253126
42.

Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.

Soininen SK, Lehtolainen-Dalkilic P, Karppinen T, Puustinen T, Dragneva G, Kaikkonen MU, Jauhiainen M, Allart B, Selwood DL, Wirth T, Lesch HP, Määttä AM, Mönkkönen J, Ylä-Herttuala S, Ruponen M.

Eur J Pharm Sci. 2012 Dec 18;47(5):848-56. doi: 10.1016/j.ejps.2012.09.001. Epub 2012 Sep 14.

PMID:
22985874
43.

siRNA delivery: from lipids to cell-penetrating peptides and their mimics.

Gooding M, Browne LP, Quinteiro FM, Selwood DL.

Chem Biol Drug Des. 2012 Dec;80(6):787-809. doi: 10.1111/cbdd.12052. Review.

PMID:
22974319
44.

Marvellous chemical biology tools and other matters.

Selwood D.

Chem Biol Drug Des. 2012 Jan;79(1):1. doi: 10.1111/j.1747-0285.2011.01273.x. No abstract available.

PMID:
22181058
45.

A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes.

Dube H, Selwood D, Malouitre S, Capano M, Simone MI, Crompton M.

Biochem J. 2012 Feb 1;441(3):901-7. doi: 10.1042/BJ20111301.

46.

Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNA.

Gooding M, Tudzarova S, Worthington RJ, Kingsbury SR, Rebstock AS, Dube H, Simone MI, Visintin C, Lagos D, Quesada JM, Laman H, Boshoff C, Williams GH, Stoeber K, Selwood DL.

Chem Biol Drug Des. 2012 Jan;79(1):9-21. doi: 10.1111/j.1747-0285.2011.01249.x. Epub 2011 Nov 4.

PMID:
21981778
47.

Techno-economic implications of improved high gravity corn mash fermentation.

Kollaras A, Kavanagh JM, Bell GL, Purkovic D, Mandarakas S, Arcenal P, Ng WS, Routledge KS, Selwood DH, Koutouridis P, Paras FE, Milic P, Tirado-Escobar ES, Moore MJ, Bell PJ, Attfield PV.

Bioresour Technol. 2011 Aug;102(16):7521-5. doi: 10.1016/j.biortech.2011.04.094. Epub 2011 May 1.

PMID:
21632242
48.

Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Vozzolo L, Loh B, Gane PJ, Tribak M, Zhou L, Anderson I, Nyakatura E, Jenner RG, Selwood D, Fassati A.

J Biol Chem. 2010 Dec 10;285(50):39314-28. doi: 10.1074/jbc.M110.155275. Epub 2010 Oct 11.

49.

Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites.

Chan AW, Laskowski RA, Selwood DL.

J Med Chem. 2010 Apr 22;53(8):3086-94. doi: 10.1021/jm901696w.

PMID:
20230000
50.

Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction.

Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C, Hartzoulakis B, Nally J, Stewart M, Cheng L, Menon M, Tickner M, Djordjevic S, Driscoll PC, Zachary I, Selwood DL.

J Med Chem. 2010 Mar 11;53(5):2215-26. doi: 10.1021/jm901755g.

Supplemental Content

Loading ...
Support Center